sebaceous adenocarcinoma: An adenocarcinoma with sebaceous differentiation. It presents as a painless mass and it may be multifocal. It grows in the ocular adnexae and in the skin of head and neck, trunk, genitals, and extremities. It is characterized by the presence of malignant cells with multivesicular and clear cytoplasm. It may recur and metastasize.
Benign neoplasm: Endocrine gland, other/unspecified
DOID EFO Endpoint Browser PheWeb
CD2_BENIGN_ENDOCRINE_NOS
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
119 |
4. Check minimum number of eventsNone |
119 |
5. Include endpointsNone |
119 |
6. Filter based on genotype QC (FinnGen only) |
118 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Endocrine gland, other/unspecified
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of other and unspecified endocrine glands
- Benign neoplasms
- Neoplasms
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 999 | 722 | 274 |
| Only index persons | 839 | 614 | 225 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.11 | 47.26 | 53.96 |
| Only index persons | 47.98 | 46.50 | 52.02 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 118 | 86 | 32 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.01 |
| Median age at first event (years) | 47.01 | 44.48 | 53.80 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 119
- Matched controls
- 1190
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D35.9
ICD-10 Finland
Benign neoplasm: Endocrine gland, unspecified
+∞
79.2
67
*
22680
ICD-8 Finland
Benign neoplasm of endocrine glands, Other specified endocrine glands
+∞
34.0
31
*
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
35.9
16.8
21
7
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
91.7
15.0
16
*
D35.7
ICD-10 Finland
Benign neoplasm: Other specified endocrine glands
+∞
13.8
13
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
132.3
11.6
12
*
E23.00
ICD-10 Finland
Panhypopituitarism
60.0
9.8
11
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
33.0
9.6
12
*
H02AB09
ATC
hydrocortisone; systemic
15.4
9.5
15
11
D35.59
ICD-10 Finland
Other paragangliom
+∞
8.4
8
*
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
85.2
7.5
8
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
8
15
5.63
3.25
3.4
1.5
4.26
5.17
nmol/l
—
8
15
9
20
4.78
3.18
1.1
1.3
—
—
—
0
0
7
13
5.64
2.91
1.0
1.0
212.14
344.77
pmol/l
—
7
13
7
13
5.64
2.91
1.3
1.1
—
—
—
0
0
19
91
2.29
2.49
1.8
2.1
0.20
0.21
g/l
0.36
19
84
26
144
2.03
2.39
3.6
2.9
0.79
0.81
mmol/l
0.33
26
137
8
28
2.99
1.90
3.6
2.2
—
—
—
0
0
5
12
4.30
1.84
1.0
1.3
—
—
—
0
0
60
463
1.60
1.72
18.0
12.7
1.18
1.22
inr
0.15
16
146
22
135
1.77
1.49
1.7
2.5
2.41
2.32
g/l
0.17
17
124
5
17
3.02
1.37
2.0
1.7
—
—
—
0
0
49
392
1.43
1.06
3.9
4.0
17.16
42.39
ng/l
1.39
37
279
68
578
1.41
1.04
11.8
8.8
3.87
4.00
e9/l
0.19
58
506
7
35
2.06
1.02
1.6
3.1
—
—
—
0
0
85
758
1.42
0.94
5.1
4.1
15.18
14.82
pmol/l
0.70
85
683
28
206
1.47
0.93
1.5
1.7
0.63
1.13
mg/l
1.17
17
164
26
192
1.45
0.85
3.1
3.3
17.24
84.53
ng/l
1.03
21
149
6
32
1.92
0.83
4.3
4.8
24.17
25.75
mmol/l
—
6
32
84
757
1.37
0.80
4.3
4.2
12.21
12.11
mm/h
0.02
76
695
58
497
1.33
0.77
8.3
6.1
1.22
1.22
mmol/l
0.01
52
429
57
489
1.32
0.74
4.4
5.1
0.00
0.00
estimate
-0.00
11
102
9
57
1.63
0.73
3.3
5.4
25.88
25.20
mmol/l
—
9
57
9
57
1.63
0.73
1.7
3.8
4.37
4.62
pmol/l
—
9
51
5
92
0.52
0.70
2.2
1.8
—
—
—
0
0
20
147
1.43
0.67
4.7
2.9
0.60
4.08
e6/l
—
10
77
5
28
1.82
0.67
1.0
1.4
—
2.18
—
0
6
57
496
1.29
0.65
3.5
3.9
0.00
0.00
estimate
-0.00
12
99
30
241
1.33
0.60
2.2
2.0
4.54
3.04
mg/l
0.62
25
212
15
107
1.46
0.59
1.7
2.6
27.67
8.96
umol/l
0.38
15
93
56
491
1.27
0.58
3.7
3.8
0.00
0.00
estimate
-0.00
12
104
9
59
1.57
0.56
1.3
1.6
—
—
—
0
0
97
913
1.34
0.55
5.6
5.0
1.81
1.92
mu/l
0.43
89
823
47
411
1.24
0.49
2.7
2.4
74.14
75.28
nmol/l
0.11
42
364
17
130
1.36
0.47
2.0
1.8
27.65
29.02
s
1.25
17
123
44
386
1.22
0.44
3.7
3.9
—
—
—
0
0
5
31
1.64
0.43
1.4
2.0
—
—
—
0
0
5
32
1.59
0.43
1.6
2.3
—
—
—
0
0
94
984
0.79
0.42
5.3
5.2
2.58
2.75
mmol/l
1.00
88
899
35
301
1.23
0.42
2.6
3.4
1178.54
1109.81
ng/l
0.07
30
255
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
2.23
—
0
8
0
17
0.00
0.41
0.0
4.1
—
108.92
—
0
17
26
218
1.25
0.38
1.7
2.1
—
—
—
0
0
15
117
1.32
0.37
3.3
6.1
104.07
103.93
mmol/l
0.04
15
117
51
460
1.19
0.37
2.2
2.4
—
—
—
0
0
32
277
1.21
0.36
1.5
1.7
1.34
1.29
mmol/l
0.14
27
238
6
43
1.42
0.35
1.3
1.7
—
—
—
0
0
19
156
1.26
0.33
4.7
2.7
0.42
1.26
e6/l
—
9
85
6
46
1.32
0.33
1.2
1.2
—
—
—
0
0
92
958
0.83
0.32
4.5
4.6
1.50
1.51
mmol/l
0.12
87
872
32
280
1.20
0.32
4.5
4.0
0.00
0.00
estimate
-0.00
12
98
7
51
1.40
0.32
2.6
1.5
—
—
—
0
0
18
149
1.25
0.30
2.4
1.8
—
—
—
0
0
15
179
0.81
0.25
1.1
1.4
—
—
—
0
0
6
82
0.72
0.25
4.7
4.5
1.21
1.22
mmol/l
—
6
73
14
167
0.82
0.23
4.9
4.5
17.03
22.52
%
—
9
76
5
42
1.20
0.22
2.0
2.5
59.40
39.88
u/l
—
5
37
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
95
922
1.15
0.20
16.4
13.4
82.02
78.62
ml/min/173m2
0.93
82
741
14
164
0.83
0.20
1.5
1.5
—
—
—
0
0
7
60
1.18
0.18
1.0
1.1
—
—
—
0
0
90
926
0.88
0.18
5.6
5.6
38.87
39.91
mmol/mol
0.62
85
857
15
130
1.18
0.16
11.3
8.5
—
—
—
0
0
106
1079
0.84
0.16
26.2
20.3
40.04
39.75
%
0.22
100
1014
23
207
1.14
0.16
1.7
1.7
475.50
495.26
pmol/l
0.10
18
172
17
188
0.89
0.12
1.2
1.3
4.12
8.27
u/ml
—
6
73
37
349
1.09
0.12
5.6
3.1
—
—
—
0
0
100
982
1.11
0.11
18.6
13.8
16.99
22.06
mg/l
1.16
82
771
43
416
1.05
0.06
2.3
1.9
102.98
95.60
pmol/l
0.55
30
199
91
921
0.95
0.04
4.1
4.1
1.31
1.27
mmol/l
0.26
85
834
104
1031
1.07
0.03
20.7
16.6
72.75
75.80
umol/l
0.78
104
1031
10
92
1.09
0.03
4.8
3.3
68.00
61.55
ml/min/173m2
—
5
40
29
299
0.96
0.03
3.2
3.6
1.00
7.31
mg/mmol
2.98
17
179
57
579
0.97
0.02
3.0
2.9
—
—
—
0
0
25
258
0.96
0.02
3.0
2.6
23955.33
5288.94
umol/l
0.35
18
221
95
957
0.96
0.01
5.0
4.6
5.67
5.91
mmol/l
1.39
86
874
27
276
0.97
0.00
5.9
3.2
1.81
0.36
e6/l
0.40
20
208
11
106
1.04
0.00
2.5
1.6
—
—
—
0
0
11
111
0.99
0.00
2.9
1.6
—
—
—
0
0
10
98
1.02
0.00
2.6
3.6
—
—
—
0
0
20
196
1.02
0.00
1.2
1.2
14.55
39.64
iu/ml
—
6
64
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
25.40
—
0
5
0
6
0.00
0.00
0.0
1.3
—
10.17
—
0
6
0
5
0.00
0.00
0.0
1.6
—
192.94
—
0
5
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
59.40
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
6.6
—
231.20
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.1
—
13.88
—
0
8
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
9
97
0.92
-0.00
3.0
1.7
1.47
1.35
%
—
9
87
5
51
0.98
-0.00
2.4
2.6
26.22
24.43
mmol/l
—
5
51
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
8.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_ENDOCRINE_NOS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_ENDOCRINE_NOS | 1.767 [1.31, 2.38] | < 0.001 |
| Birth year | 0.994 [0.98, 1.0] | 0.159 |
During the follow-up period (1.1.1998 — 31.12.2019), 66 out of 342 females with CD2_BENIGN_ENDOCRINE_NOS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_ENDOCRINE_NOS | 1.457 [1.0, 2.12] | 0.048 |
| Birth year | 0.986 [0.98, 1.0] | 0.005 |
During the follow-up period (1.1.1998 — 31.12.2019), 53 out of 174 males with CD2_BENIGN_ENDOCRINE_NOS died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_ENDOCRINE_NOS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.173% | 0.259% |
| 5 | 1.091% | 1.623% |
| 10 | 2.446% | 4.189% |
| 15 | 4.468% | 7.8% |
| 20 | 7.965% | 13.257% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_ENDOCRINE_NOS – Benign neoplasm: Endocrine gland, other/unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data